MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Vaccine Development & Manufacturing
Affinivax
Attachments
Affinivax | simple. powerful. vaccines.
Parents
*Architects: Pneumonia, Pneumococcal
*Architects: Vaccine Development & Manufacturing
*Industry: Massachusetts
Companies: Acquired_(M&A)
Finance & Acquisitions: GlaxoSmithKline (GSK)
Children
2022: GSK gets pneumococcal vaccine contender with $2.1B Affinivax acquisition
Affinivax is a clinical stage biopharmaceutical company with a next generation vaccine technology platform called the Multiple Antigen Presentation System (MAPS™).
Cambridge, Massachusetts
MAPS uses a patented approach to achieve high-affinity binding of two key immunogenic components – polysaccharide and protein antigens – so that both components are able to drive a broad and protective B-cell and T-cell immune response in a single vaccine.